Seeking $115 Million, Santa Monica-based Biotech, Kite Pharma, Files for IPO

Kite Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products

From Kite Pharma:

“Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Kite. The number of shares to be offered and the price range for the offering have not yet been determined.

Jefferies LLC, Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Stifel is acting as co-manager…”

READ FULL PRESS RELEASE [web]
Kite Pharma, Inc. [web]

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s